JP5047627B2 - ピリジニウムおよびキノリニウム誘導体 - Google Patents

ピリジニウムおよびキノリニウム誘導体 Download PDF

Info

Publication number
JP5047627B2
JP5047627B2 JP2006548321A JP2006548321A JP5047627B2 JP 5047627 B2 JP5047627 B2 JP 5047627B2 JP 2006548321 A JP2006548321 A JP 2006548321A JP 2006548321 A JP2006548321 A JP 2006548321A JP 5047627 B2 JP5047627 B2 JP 5047627B2
Authority
JP
Japan
Prior art keywords
quin
group
halogen
hydroxyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006548321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517837A5 (enExample
JP2007517837A (ja
Inventor
フアン、カルロス、ラカル、サンフアン
ホアキン、カンポス、ロサ
ミゲル、アンヘル、ガリョ、メサ
アントニオ、エスピノサ、ウベダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Granada
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Granada filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of JP2007517837A publication Critical patent/JP2007517837A/ja
Publication of JP2007517837A5 publication Critical patent/JP2007517837A5/ja
Application granted granted Critical
Publication of JP5047627B2 publication Critical patent/JP5047627B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2006548321A 2004-01-14 2005-01-11 ピリジニウムおよびキノリニウム誘導体 Expired - Fee Related JP5047627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200400072 2004-01-14
ES200400072A ES2237332B1 (es) 2004-01-14 2004-01-14 Derivados de piridinio y quinolinio.
PCT/ES2005/070002 WO2005068429A1 (es) 2004-01-14 2005-01-11 Derivados de piridinio y quinolinio

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012062569A Division JP5619805B2 (ja) 2004-01-14 2012-03-19 ピリジニウムおよびキノリニウム誘導体

Publications (3)

Publication Number Publication Date
JP2007517837A JP2007517837A (ja) 2007-07-05
JP2007517837A5 JP2007517837A5 (enExample) 2012-07-12
JP5047627B2 true JP5047627B2 (ja) 2012-10-10

Family

ID=34778265

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006548321A Expired - Fee Related JP5047627B2 (ja) 2004-01-14 2005-01-11 ピリジニウムおよびキノリニウム誘導体
JP2012062569A Expired - Fee Related JP5619805B2 (ja) 2004-01-14 2012-03-19 ピリジニウムおよびキノリニウム誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012062569A Expired - Fee Related JP5619805B2 (ja) 2004-01-14 2012-03-19 ピリジニウムおよびキノリニウム誘導体

Country Status (15)

Country Link
US (1) US7781458B2 (enExample)
EP (2) EP1710236B1 (enExample)
JP (2) JP5047627B2 (enExample)
KR (1) KR101157206B1 (enExample)
CN (1) CN1910153B (enExample)
AT (1) ATE461918T1 (enExample)
BR (1) BRPI0506486A (enExample)
CA (1) CA2553328C (enExample)
DE (1) DE602005020112D1 (enExample)
DK (1) DK1710236T3 (enExample)
ES (2) ES2237332B1 (enExample)
MX (1) MXPA06007940A (enExample)
PL (1) PL1710236T3 (enExample)
PT (1) PT1710236E (enExample)
WO (1) WO2005068429A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586613B2 (en) * 2004-01-14 2013-11-19 Universidad De Granada Pyridinium and quinolinium derivatives
CA2729857A1 (en) 2008-07-04 2010-01-07 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
US20110212994A1 (en) * 2009-06-26 2011-09-01 Brian Clem Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders
WO2012041493A1 (en) * 2010-09-28 2012-04-05 Julius-Maximilians-Universität Würzburg Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
BR112013032857A2 (pt) 2011-06-20 2017-01-24 Traslational Cancer Drugs Pharma S L método para prever a resposta clínica à quimioterapia em um indivíduo com câncer
EP2758395A1 (en) * 2011-09-22 2014-07-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of choline kinase
ES2472367B1 (es) * 2012-12-28 2015-06-02 Universidad De Granada Inhibidores no simétricos de colina quinasa con actividad antitumoral y antimalárica
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
ES2482290B1 (es) * 2014-06-05 2015-05-19 Universidad De Granada Inhibidores polares simétricos de colina cinasa con actividad antitumoral
JP6920411B2 (ja) 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ
CN110997678B (zh) 2017-07-11 2023-02-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的吡唑并喹唑啉衍生物
WO2025196502A1 (en) * 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206215A (en) * 1976-02-25 1980-06-03 Sterling Drug Inc. Antimicrobial bis-[4-(substituted-amino)-1-pyridinium]alkanes
GB1533952A (en) * 1976-02-25 1978-11-29 Sterling Drug Inc Anti-microbial bis-pyridinium compounds
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL89026A (en) * 1988-01-29 1993-02-21 Lilly Co Eli Substituted quinolines and cinnolines, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
ES2117950B1 (es) 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.

Also Published As

Publication number Publication date
CN1910153B (zh) 2010-05-26
BRPI0506486A (pt) 2007-02-13
DK1710236T3 (da) 2010-07-12
JP2012149077A (ja) 2012-08-09
ATE461918T1 (de) 2010-04-15
PT1710236E (pt) 2010-06-18
ES2343418T3 (es) 2010-07-30
CA2553328C (en) 2012-05-15
MXPA06007940A (es) 2007-01-23
US20070185170A1 (en) 2007-08-09
EP1710236A1 (en) 2006-10-11
WO2005068429A1 (es) 2005-07-28
ES2237332B1 (es) 2006-11-01
EP2085386A2 (en) 2009-08-05
KR101157206B1 (ko) 2012-07-06
PL1710236T3 (pl) 2010-08-31
HK1100441A1 (en) 2007-09-21
ES2237332A1 (es) 2005-07-16
EP1710236B1 (en) 2010-03-24
KR20060110364A (ko) 2006-10-24
US7781458B2 (en) 2010-08-24
DE602005020112D1 (de) 2010-05-06
CA2553328A1 (en) 2005-07-28
JP5619805B2 (ja) 2014-11-05
EP2085386A3 (en) 2009-10-28
CN1910153A (zh) 2007-02-07
JP2007517837A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
JP5619805B2 (ja) ピリジニウムおよびキノリニウム誘導体
US10654807B2 (en) Toll-like receptor 8 agonists
JP2024535475A (ja) 置換ヘテロアリールフタラジン誘導体の医薬使用及びその調製方法
CN108341813B (zh) 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
NZ524156A (en) Novel heteroaryl derivatives and their use as medicaments
JP2007517837A5 (enExample)
CN102438612B (zh) 腈衍生物及其药学用途与组合物
CZ286180B6 (cs) 6,9-bis(Substituované amino)benzo/g/isochinolin-5 10-diony
CN112724134B (zh) 氮杂吲唑联吡啶衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用
US8586613B2 (en) Pyridinium and quinolinium derivatives
CN111153817B (zh) 苯氧基-n-苯基苯胺衍生物及其应用
CN109593064A (zh) 作为btk抑制剂的氨基二硫代甲酸酯类化合物
Lacal et al. Derivatives of pyridine and quinoline
CN102558144A (zh) 一种芳基脲衍生物
HK1100441B (en) Derivatives of pyridine and quinoline
CN102731525A (zh) 苯并吗啉衍生物
US11021479B2 (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
EP0031407B1 (en) Substituted 3,6 bis-(aminoalkoxy)acridines, and a process for their preparation
CN112876456A (zh) 噌啉化合物pi3k激酶抑制剂及其制备方法与在制药中的应用
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用
Sayed et al. Focus on the synthesis and reactions of some new pyridine carbonitrile derivatives as antimicrobial and antioxidant agents
CN111393363B (zh) 4-苯氧基喹啉并n-磺酰脒类化合物及其制备方法和用途
CN109400627B (zh) 一种含n-甲基洛美沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN105878243B (zh) 吡非尼酮衍生物在制药中的应用
CN113214247A (zh) 氮杂吲哚衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110804

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120319

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120507

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120619

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120718

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150727

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees